Efficacy and Safety of Nivolumab in Bone Metastases from Renal Cell Carcinoma: Results of the GETUG-AFU26-NIVOREN Multicentre Phase II Study

•Lower efficacy of nivolumab if bone metastases (BM) in renal cell carcinoma (RCC).•Negative impact of BM, known with antiangiogenic agents, still present with nivolumab.•First study evaluating bone-targeting agents (BTA) with immunotherapy in RCC with BM.•Benefit of BTA on skeletal-related events incidence without an increase of BTA toxicity.•The use of BTA with immunotherapy alone should be considered.